Patents by Inventor Jonathan Barry

Jonathan Barry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220033490
    Abstract: The present invention provides methods for treating cancer using a6*nAChR inhibitors, such as a6*nAChR inhibitory antibodies, among others. The invention also features compositions containing a6*nAChR inhibitors, methods of diagnosing patients with a6*nAChR-associated cancer, and methods of predicting the response of cancer in a subject to treatment with a6*nAChR inhibitors.
    Type: Application
    Filed: January 31, 2019
    Publication date: February 3, 2022
    Inventors: Avak KAHVEJIAN, Jordi MATA-FINK, Jonathan Barry HUROV, Chengyi Jenny SHU, Manuel Andreas FANKHAUSER, Julian Alexander STANLEY
  • Patent number: 11208475
    Abstract: The present invention provides methods for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators, such as serotonin receptor activating antibodies, among others. The invention also features compositions containing serotonin receptor activators, methods of diagnosing patients with a serotonin receptor-associated inflammatory or autoimmune disease or condition, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with serotonin receptor activators.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: December 28, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, George Huck Neubauer, Manuel Andreas Fankhauser, Julian Alexander Stanley
  • Publication number: 20210283217
    Abstract: Described herein are methods for treating a subject having or at risk of developing an autoimmune or inflammatory condition or an infection by administering a neuromodulating agent.
    Type: Application
    Filed: July 25, 2017
    Publication date: September 16, 2021
    Inventors: Erica WEINSTEIN, Jordi MATA-FINK, Avak KAHVEJIAN, Noubar B. AFEYAN, Laura Kristina JEANBART, Alexandra LANTERMANN, Jonathan Barry HUROV, Manuel Andreas FANKHAUSER, Chengyi J. SHU, Eric Franklin ZHU
  • Patent number: 11059886
    Abstract: The present invention provides methods for treating inflammatory or autoimmune disease using mGluR8 activators, such as mGluR8 activating antibodies, among others. The invention also features compositions containing mGluR8 activators, methods of diagnosing patients with mGluR8-associated inflammatory or autoimmune disease, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with mGluR8 activators.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: July 13, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, George Huck Neubauer, Julian Alexander Stanley
  • Publication number: 20210177823
    Abstract: Described herein are methods for treating a subject having or at risk of developing cancer by administering a neuromodulating agent.
    Type: Application
    Filed: September 17, 2020
    Publication date: June 17, 2021
    Inventors: Erica WEINSTEIN, Jordi MATA-FINK, Avak KAHVEJIAN, Noubar B. AFEYAN, Laura Kristina JEANBART, Alexandra LANTERMANN, Jonathan Barry HUROV
  • Patent number: 11034751
    Abstract: The present invention provides methods for treating cancer using serotonin receptor inhibitors, such as serotonin receptor inhibitory antibodies, among others. The invention also features compositions containing serotonin receptor inhibitors, methods of diagnosing patients with serotonin receptor-associated cancer, and methods of predicting the response of cancer in a subject to treatment with serotonin receptor inhibitors.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: June 15, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, George Huck Neubauer, Manuel Andreas Fankhauser, Julian Alexander Stanley
  • Publication number: 20210154272
    Abstract: Described herein are methods for treating a subject having or at risk of developing cancer administering a neuromodulating agent.
    Type: Application
    Filed: October 5, 2020
    Publication date: May 27, 2021
    Inventors: Erica WEINSTEIN, Jordi MATA-FINK, Avak KAHVEJIAN, Noubar B. AFEYAN, Laura Kristina JEANBART, Alexandra LANTERMANN, Jonathan Barry HUROV, Manuel Andreas FANKHAUSER, Chengyi J. SHU, Eric Franklin ZHU
  • Patent number: 11013717
    Abstract: The present invention provides methods for treating cancer using sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump inhibitors, such as SERCA pump inhibitory antibodies, among others. The invention also features compositions containing SERCA pump inhibitors, methods of diagnosing patients with SERCA pump-associated cancer, and methods of predicting the response of cancer in a subject to treatment with SERCA pump inhibitors.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: May 25, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, Eric Franklin Zhu, Katherine Mary Molloy
  • Publication number: 20200360364
    Abstract: The present invention provides methods for treating inflammatory or autoimmune diseases or conditions using activators tin of nicotinic acetylcholine receptors (nAChRs) containing a cholinergic receptor nicotinic alpha 6 subunit (nAChR?S), such as activating antibodies that bind to a nAChR containing a nAChP?6 subunit and small molecule agonists of nAChRs containing a nAChR?S subunit. The invention also features compositions containing ?6*nAChR activators, methods of diagnosing patients with an ?6*nAChR-associated inflammatory or autoimmune disease or condition, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with ?6*nAChR activators.
    Type: Application
    Filed: January 31, 2019
    Publication date: November 19, 2020
    Inventors: Avak KAHVEJIAN, Jordi MATA-FINK, Jonathan Barry HUROV, Chengyi Jenny SHU, Manuel Andreas FANKHAUSER, Julian Alexander STANLEY
  • Patent number: 10683352
    Abstract: The present invention provides methods for treating cancer using mGluR8 inhibitors, such as mGluR8 inhibitory antibodies and small molecules. The invention also features compositions containing mGluR8 inhibitors, methods of diagnosing patients with mGluR8-associated cancer, and methods of predicting the response of cancer in a subject to treatment with mGluR8 inhibitors.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: June 16, 2020
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, George Huck Neubauer, Julian Alexander Stanley
  • Publication number: 20190380805
    Abstract: Embodiments relate to illuminated electrosurgical devices and related systems and methods. An electrosurgical device can include an electrosurgical blade having a proximal end and a distal end and comprising a plurality of light elements. A plurality of separation walls and a plurality of apertures can be arranged relative to the plurality of light elements to guide light from the plurality of light elements to illuminate an area around the distal end of the electrosurgical blade.
    Type: Application
    Filed: January 31, 2019
    Publication date: December 19, 2019
    Inventors: Roger Greeley, Peter Goodwin, John Gearheart, Ethan Carter, Kevin McElwee, Jonathan Barry
  • Patent number: 10457740
    Abstract: The present invention provides methods for treating cancer using P2RX2 inhibitors, such as P2RX2 inhibitory antibodies, among others. The invention also features compositions containing P2RX2 inhibitors, methods of diagnosing patients with P2RX2-associated cancer, and methods of predicting the response of cancer in a subject to treatment with P2RX2 inhibitors.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: October 29, 2019
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Alexandra Lantermann
  • Publication number: 20190240293
    Abstract: Described herein are methods for treating a subject having or at risk of developing cancer administering a neuromodulating agent.
    Type: Application
    Filed: July 25, 2017
    Publication date: August 8, 2019
    Inventors: Erica WEINSTEIN, Jordi MATA-FINK, Avak KAHVEJIAN, Noubar B. AFEYAN, Laura Kristina JEANBART, Alexandra LANTERMANN, Jonathan Barry HUROV, Manuel Andreas FANKHAUSER, Chengyi J. SHU, Eric Franklin ZHU
  • Publication number: 20190233527
    Abstract: The present invention provides methods for treating inflammatory or autoimmune disease using calcitonin receptor activators, such as calcitonin receptor activating antibodies, among others. The invention also features compositions containing calcitonin receptor activators, methods of diagnosing patients with calcitonin receptor-associated inflammatory or autoimmune disease, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with calcitonin receptor activators.
    Type: Application
    Filed: September 24, 2018
    Publication date: August 1, 2019
    Inventors: Avak KAHVEJIAN, Jordi MATA-FINK, Jonathan Barry HUROV, Chengyi Jenny SHU, George Huck NEUBAUER, Manuel Andreas FANKHAUSER, Julian Alexander STANLEY
  • Patent number: 10195874
    Abstract: Enhanced printing solutions are enabled by providing ultraviolet curing conditions without requiring complete evacuation of atmospheric oxygen. Increased ink coverage and adjusted surface appearance are also provided.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: February 5, 2019
    Assignee: ELECTRONICS FOR IMAGING, INC.
    Inventors: Jonathan Barry, John Duffield, Lianhui Cong, Arthur L. Cleary
  • Patent number: 10044451
    Abstract: Method for testing multiple signal transceiver devices under test (DUTs), such as data packet signal transceivers, with a shared DUT testing resource, such as a tester having a single vector signal generator (VSG) and a single vector signal analyzer (VSA). Requests by the DUTs for access to tester resources (e.g., to receive signals from the signal generator or provide signals to the signal analyzer) are prioritized based upon tester availability and whether the requesting DUT requires sole access or can share access to the tester. If the tester is unavailable, DUT requests are queued according to their respective priorities to await tester availability. As a result, access to shared tester resources can be managed dynamically to minimize test time while testing multiple DUTs concurrently.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: August 7, 2018
    Assignee: LITEPOINT CORPORATION
    Inventors: Jonathan Barry Hirst, Adam Martin Smith
  • Patent number: 9486283
    Abstract: The disclosure provides a fluid-assisted electrosurgical device. The device comprises a first electrode, a second electrode and at least one fluid outlet. In one embodiment, the first electrode has a distal portion with an electrically conductive spherical surface, the second electrode has a distal portion with an electrically conductive spherical surface, and at least one of the first electrode and the second electrode have a blade portion.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: November 8, 2016
    Assignee: MEDTRONIC ADVANCED ENERGY LLC
    Inventors: Roger D. Greeley, Donald Earles, David Flanagan, Eliot Bloom, Brian Conley, Jonathan Barry
  • Patent number: 9325435
    Abstract: A system and method for facilitating comparison of radio frequency (RF) data signals transmitted by a device under test (DUT) and received by a test system. A RF data signal received from a DUT is analyzed to provide analysis data indicative of conformance of the DUT operation with one or more applicable signal standards. The RF data signal is also converted to related conversion data that can be stored with state machine data corresponding to states of the signal testing subsystem. This state machine data can then be processed as needed with the analysis data and conversion data for off-line tasks such as debugging new test programs and procedures.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: April 26, 2016
    Assignee: LITEPOINT CORPORATION
    Inventors: Christian Volf Olgaard, Jonathan Barry Hirst, Wing Hung Lee
  • Patent number: 9319912
    Abstract: System and method for using a shared packet data signal source to test multiple packet data signal transceiver devices under test (DUTs) capable of communicating using multiple radio access technologies (RATs). The signal source provides a packet data signal that includes a plurality of sequential signal segments having respective signal timing parameters and mutually distinct signal characteristics in accordance with the RATs. Based upon the signal timing parameters, at least a portion of each signal segment is routed to a respective one of multiple signal connections for conveyance to a corresponding DUT.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: April 19, 2016
    Assignee: LITEPOINT CORPORATION
    Inventors: Jonathan Barry Hirst, James L. Banzen, William L. Barker, Jr.
  • Patent number: D923176
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: June 22, 2021
    Assignee: Medtronic Advanced Energy LLC
    Inventors: Amy Bradley, Jonathan Barry, Alexander Segit